Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostatic Neoplasms × Etoricoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Spondylitis, Ankylosing 1 Somatoform Disorders 1 Prostatic Neoplasms 1 Peripheral Nervous System Diseases 1 Breast Neoplasms 1 Bone Neoplasms 1

Interventions

Docetaxel 137 Prednisone 120 Abiraterone Acetate 91 Leuprolide 86 enzalutamide 83 Radiotherapy 58 bicalutamide 55 Magnetic Resonance Spectroscopy 54 Goserelin 54 Androgen Antagonists 51 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47 apalutamide 44 abiraterone 34 Radiosurgery 32 Specimen Handling 30 gallium 68 PSMA-11 29 Gonadotropin-Releasing Hormone 29 cabazitaxel 28 Carboplatin 28 darolutamide 25 Estramustine 24 luprolide acetate gel depot 23 relugolix 22 Metformin 22 Triptorelin Pamoate 20 sipuleucel-T 19 radium Ra 223 dichloride 19 Radiation 19 pembrolizumab 18 deltacortene 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed

67 enrolled 6 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡